09:47 AM EST, 01/26/2026 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Monday it began a Phase 2 clinical trial of its experimental compound in adults suffering from tardive dyskinesia, a medication-induced movement disorder.

The new drug candidate is a next-generation inhibitor designed to potentially provide a longer-acting treatment option for the movement condition, the company said.

The study will involve roughly 100 participants to test the effectiveness and safety of the medication against a placebo, Neurocrine said.

The primary endpoint will be based on changes in a standard scale for involuntary movements after eight weeks of treatment, the company added.

Price: 134.11, Change: -2.07, Percent Change: -1.52